fourth quarter and full year fiscal 2016 financial results...
TRANSCRIPT
Fourth Quarter and Full Year Fiscal 2016
Financial Results – Supplemental Materials
March 16, 2016
Forward-looking Statements
Information included in this presentation may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical fact, but rather reflect our current expectations
concerning future events and results. These statements may include the use of the words
“believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “continues,” “may,” “will,”
and similar expressions to identify forward-looking statements. Such forward-looking
statements, including those concerning growth through acquisitions, involve risks,
uncertainties and other factors, some of which are beyond our control, which may cause
our actual results, performance or achievements to be materially different from those
expressed or implied by such forward-looking statements. These risks, uncertainties, and
factors include, but are not limited to, those factors set forth in the Company’s Annual
Report on Form 10-K for the fiscal year ended January 31, 2015 and subsequent filings
Astro-Med makes with the Securities and Exchange Commission. The Company
undertakes no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. The reader is
cautioned not to unduly rely on such forward-looking statements when evaluating the
information presented in this presentation.
Q4 and FY 2016 Financial Results
Supplemental Materials 2©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted
accounting principles (GAAP), this presentation contains the following non-GAAP
financial measures: non-GAAP net income per diluted share and free cash flow. The
Company believes that the inclusion of these non-GAAP financial measures in this
presentation helps investors to gain a meaningful understanding of changes in the
Company's core operating results, and also can help investors who wish to make
comparisons between AstroNova and other companies on both a GAAP and a non-GAAP
basis. AstroNova’s management uses these non-GAAP measures, in addition to GAAP
financial measures, as the basis for measuring its core operating performance and
comparing such performance to that of prior periods and to the performance of its
competitors. These measures are also used by the Company’s management to assist
with their financial and operating decision-making. Please see the reconciliation table on
Slide 14 for a reconciliation of the non-GAAP financial measures to the most directly
comparable GAAP measures.
Q4 and FY 2016 Financial Results
Supplemental Materials 3©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
Q4 Fiscal 2016 Performance Summary
Q4 and FY 2016 Financial Results
Supplemental Materials 4©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
$20.8
$24.9
Q4 FY15 Q4 FY16
Bookings
+ 19.7%
$22.1
$23.8
Q4 FY15 Q4 FY16
Revenue
+ 7.7%
($ in millions)
Q4 Fiscal 2016 Performance Summary
Q4 and FY 2016 Financial Results
Supplemental Materials 5©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
$0.10
$0.17
Q4 FY15 Q4 FY16
Non-GAAP EPS
+ 70.0%
$0.07
$0.11
Q4 FY15 Q4 FY16
GAAP EPS
+ 57.1%
Full Year Fiscal 2016 Performance Summary
Q4 and FY 2016 Financial Results
Supplemental Materials 6©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
(Text)
$88.3
$102.3
FY15 FY16
Bookings
+ 15.9%
Record
$88.3
$94.7
FY15 FY16
Revenue
+ 7.1%
Record
($ in millions)
Full Year Fiscal 2016 Performance Summary
Q4 and FY 2016 Financial Results
Supplemental Materials 7©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
(Text)
$0.65
$0.77
FY15 FY16
Non-GAAP EPS
+ 18.5%
$.60
$0.61
FY15 FY16
GAAP EPS
+ 1.7%
Free Cash Flow
12 Months Ended
January 31, 2015
12 Months Ended
January 31, 2016
Net Cash Provided by
Operating Activities
$1,491 $7,727
Capital Expenditures ($2,247) ($3,061)
Free Cash Flow ($756) $4,666
Q4 and FY 2016 Financial Results
Supplemental Materials©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. | 8
($ in Thousands)
QuickLabel Systems Q4 Fiscal 2016 Performance
Q4 and FY 2016 Financial Results
Supplemental Materials 9©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
$14.5
$16.2
Q4 FY15 Q4 FY16
Bookings
+ 11.6%
$14.8
$16.6
Q4 FY15 Q4 FY16
Revenue
+ 12.1%
$0.9
$1.7
Q4 FY15 Q4 FY16
Operating Profit
+ 88.9%
($ in millions)
QuickLabel Systems FY Fiscal 2016 Performance
Q4 and FY 2016 Financial Results
Supplemental Materials 10©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
$60.3
$69.3
FY15 FY16
Bookings
+ 15.0%
$59.8
$67.1
FY15 FY16
Revenue
+ 12.3%
$7.3
$9.3
FY15 FY16
Operating Profit
+ 29.2%
($ in millions)
Test & Measurement Q4 Fiscal 2016 Performance
Q4 and FY 2016 Financial Results
Supplemental Materials 11©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
$6.3
$8.8
Q4 FY15 Q4 FY16
Bookings
+ 38.2%
$7.2
$7.1
Q4 FY15 Q4 FY16
Revenue
(1.4%)
$1.6
$1.0
Q4 FY15 Q4 FY16
Operating Profit
(37.5%)
($ in millions)
Test & Measurement FY Fiscal 2016 Performance
Q4 and FY 2016 Financial Results
Supplemental Materials 12©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
$28.0
$32.9
FY15 FY16
Bookings
+ 17.5%
$28.6
$27.5
FY15 FY16
Revenue
(3.6%)
$5.6
$3.7
FY15 FY16
Operating Profit
(33.9%)
($ in millions)
Thank You!
Q4 and FY 2016 Financial Results
Supplemental Materials13©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |
Reconciliation of Non-GAAP EPS
GAAP based results:EPS-Diluted $0.11 $0.07 $0.61 $0.60
Add Back - Non-GAAP adjustments (net of taxes):
Rebranding Initiatives 0.02 - 0.02 -
RITEC Transaction/Transition Costs 0.03 - 0.09 -
2016 Long-Term Incentive Plan Share-Based Compensation 0.01 - 0.05 -
Write-down of TSA Inventory - - - 0.02
Share Buyback Costs - 0.01 - 0.01
Write-down of Asset Held for Sale - 0.02 - 0.02Non-GAAP EPS - Diluted $0.17 $0.10 $0.77 $0.65
14
Three –Months EndedJanuary 31, 2016 January 31, 2015
Twelve –Months EndedJanuary 31, 2016 January 31, 2015
Q4 and FY 2016 Financial Results
Supplemental Materials©2016 Astro-Med, Inc. d/b/a AstroNova All rights reserved. |